[Management of TB suspected cases of drug resistant tuberculosis requiring a second treatment]
- PMID: 15495588
[Management of TB suspected cases of drug resistant tuberculosis requiring a second treatment]
Abstract
The management of patients with resistance to anti tuberculous drugs is complex and therefore must be managed by physician specialists. The most difficult patients are the cases in retreatment, where some very different possibilities are possible, as abandonment, failures and relapses. Patients with multi-drug resistant (MDR) tuberculosis are the most difficult to treat; MDR appears in all the failures or non-adherences to the treatment regime. To elaborate a scheme of retreatment for these patients, two guidelines must be followed: (1) do not rely on outcomes of drug susceptibility tests and (2) a detailed history of drug treatment must be considered of paramount importance. With this information, a retreatment scheme can be formulated that involves the use of at least three drugs not previously taken by the patient. For a successful control of tuberculosis, the national tuberculosis programs in Latin American countries must assure careful management of newly diagnosed patients. Secondly, if resources are available, a bank of second-line drugs must be ready for managing retreatment situations (e.g., 3 Z-Kn-Eth-Of/15 Z-Eth-Of) if first line drug treatments fail. Using individualized retreatment with second line drugs is recommended only in industrialized countries, and for a few middle income countries as a last resort.
Similar articles
-
First-line anti-tuberculosis drug resistance patterns and trends at the national TB referral center in Iran--eight years of surveillance.Int J Infect Dis. 2009 Sep;13(5):e236-40. doi: 10.1016/j.ijid.2008.11.027. Epub 2009 Mar 13. Int J Infect Dis. 2009. PMID: 19285897
-
[Development of antituberculous drugs: current status and future prospects].Kekkaku. 2006 Dec;81(12):753-74. Kekkaku. 2006. PMID: 17240921 Review. Japanese.
-
Surveillance of Mycobacterium tuberculosis susceptibility to second-line drugs in Hong Kong, 1995-2002, after the implementation of DOTS-plus.Int J Tuberc Lung Dis. 2004 Jun;8(6):760-6. Int J Tuberc Lung Dis. 2004. PMID: 15182147
-
Treatment outcomes for HIV-uninfected patients with multidrug-resistant and extensively drug-resistant tuberculosis.Clin Infect Dis. 2008 Aug 15;47(4):496-502. doi: 10.1086/590005. Clin Infect Dis. 2008. PMID: 18611154
-
Which agents should we use for the treatment of multidrug-resistant Mycobacterium tuberculosis?J Antimicrob Chemother. 2004 Sep;54(3):593-602. doi: 10.1093/jac/dkh377. Epub 2004 Jul 28. J Antimicrob Chemother. 2004. PMID: 15282233 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical